drugset / Trial / NCT01005771

Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions

NCT01005771

Phase 2 Completed 200 enrolled Ferrer Internacional S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled, parallel-group, dose-finding study.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ozenoxacin Other / unclassified 0.25 % Topical
Subject Ozenoxacin Other / unclassified 1 % Topical
Subject Ozenoxacin Other / unclassified 2 % Topical

Indications

No indication recorded.